New fundraising campaign for Amoéba

You are here

Lyon, May 13, 2016 - Amoéba announced an increase in capital thanks to the private placement of new shares for a total of around EUR 14.7 million. This new fundraising campaign was open to European and American investors despite the current difficult economic context. The funds raised will allow Amoéba to accelerate its development on the two continents. In Europe, two new 2 x 500 litre production units will be deployed, while in the North-American market development will be supported through the implantation of an on-site production unit. This new implantation will notably facilitate the R&D tests to be performed in Canada.

I am pleased to announce the success of a new fundraising campaign which confirms the confidence our current investors and high-ranking international investors have in our product. This investment will help accelerate Amoéba's industrial development plan, allowing us to install 4 production bioreactors on our site in Chassieu a year ahead of schedule. The arrival of US investors lends legitimacy to Amoéba's development strategy in North American territories, where the Company already has a production unit in Montreal.” indicated Fabrice PLASSON, President of the board of directors of Amoeba.

Related Posts